Hereditary angioedema (HAE) is a rare genetic disease characterised by recurrent sudden attacks of oedema of the skin or the mucous membranes. HAE affects between 1 in 10,000 and 1 in 50,000 people. HAE is caused by an inherited deficiency of C1-esterase inhibitor (C1-INH), a protein which has a regulatory role in the classic complement [...]
Results from two Phase III studies of Firazyr published recently in the New England Journal of Medicine demonstrate the efficacy and favourable safety profile of icatibant for the treatment of Hereditary Angioedema (HAE) attacks. The FAST-1 and FAST-2 studies The FAST-1 and FAST-2 studies were double-blind randomised multicenter trials designed to evaluate the effect of [...]
Results from the CONDOR study published recently in the Lancet show that arthritis patients at increased gastrointestinal risk taking celecoxib had a significantly lower incidence of clinically significant upper and lower gastrointestinal events, compared with patients taking diclofenac in combination with omeprazole.1 Due to their anti-inflammatory and analgesic properties, non steroidal anti-inflammatory drugs (NSAIDs) are [...]
Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits this isoform of cyclooxygenase, whereas non-selective NSAIDs substantially inhibit both COX-1 and COX-2. Celecoxib is approximately 10 to 20 times more selective for COX-2 inhibition over COX-1. This selectivity allows celecoxib – and other COX-2 inhibitors – to reduce inflammation and pain while minimising gastrointestinal [...]
Rosiglitazone (Avandia/Avandamet) is a medicinal product authorised for use across the European Union through the European licensing process, as a second line treatment in the management of type II diabetes, which should only be used when other treatments have either failed, or are unsuitable for a patient. Use of Avandia (rosiglitazone) has been contraindicated in [...]
Company: Actavis Ireland Ltd. Legal category: Prescription. Hospital. Sport permitted. Active ingredients: Piperacillin Na+/tazobactam Na+ 2.25g (2g/0.25g), 4.5g (4g/0.5g). Description: Powder for solution for injection or infusion. Presentation: Prices on request. Indications: Treatment of moderate to severe systemic and/or local bacterial infections in which β-lactamase producing bacteria are suspected or have been detected. Adults/adolescents/elderly: Nosocomial [...]
Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Cefuroxime 250mg, 500mg. Description: Light blue film-coated tablets marked either 250 or 500 on one side and P125 or P126 on reverse, resp. Presentation: 250mg-14, €5.34: 500mg-14, €10.16. Indications: Mild to moderately severe infections such as upper respiratory tract infections (acute otitis media, [...]
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Omeprazole 10mg, 20mg, 40mg. Description: Gastro-resistant, hard capsules. 10mg, 20mg: Opaque yellow. 40mg: Opaque blue and white. Presentation: 10mg-28; 20mg-28; 40mg-14. Prices available on request. Indications: Treatment of duodenal ulcers; benign gastric ulcers; reflux oesophagitis (RO); Zollinger-Ellison syndrome (ZES); NSAID related gastric and [...]
Company: MSD. Legal category: Prescription. High Tech. Sports permitted. Active ingredient: Golimumab 50mg/0.5ml. Description: Solution for injection in pre-filled pen. Presentation: Price available on request. Indications: Treatment of moderate to severe, active rheumatoid arthritis in combination with methotrexate (MTX) when the response to disease-modifying anti-rheumatic drug (DMARD) therapy [...]
Loading ...
